| CASE REPORT |
|
| Year : 2022 | Volume
: 14
| Issue : 1 | Page : 35-37 |
|
|
Treatment of hepatitis C in a case of pediatric B-cell acute leukemia
Nikita Jakhar1, Akriti Gera1, Richa Mittal1, Sumit Mehndiratta1, Shalimar2, Amitabh Singh1
1 Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
2 Department of Gastroenterology, AIIMS, New Delhi, India
Correspondence Address:
Dr. Amitabh Singh
Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jgid.jgid_1_21
|
|
|
The prevalence of hepatitis C virus (HCV) infection in Pediatric patients with lymphoproliferative diseases has most commonly been reported with B cell Non-Hodgkin lymphoma. Case studies have reported the requirement of dose reduction or suspension of chemotherapy in 80% of Pediatric ALL cases who are anti-HCV positive owing to hepatotoxicity. The standard of care anti HCV therapy in children aged 3-17 years had been peginterferon and ribavirin for 48 weeks. FDA approved pan-genotypic, anti- HCV regimen, sofosbuvir/velpatasvir [SOF/VEL], for the Pediatric population >6yrs of age or >17 kg body weight in March 2020. We herein report a case of an HCV infected Pediatric B cell ALL patient who was treated with SOF/VEL concomitantly with an intensive chemotherapy regimen. Child tolerated the full dose chemotherapy along with antivirals for 12 weeks and was in morphological remission with sustained virological response.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
